Nixon Peabody Trust’s AC Immune ACIU Stock Holding History

Nixon Peabody Trust’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,850	Closed	-$64.3K	–	127
2023 Q4	$64.3K	Buy	+12,850	New	+$41.3K	0.01%	129

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Nixon Peabody Trust's ACIU Position: Q1 2024 in Review

Nixon Peabody Trust sold out of AC Immune (ACIU) in Q1 2024, closing a stake of 12,850 shares — an estimated $64.3K sold.

Nixon Peabody Trust first reported a position in ACIU in Q4 2023 and held it in 1 quarter. The position peaked at $64.3K in Q4 2023. 37 funds tracked by Wall St. Rank hold ACIU as of Q1 2024.

Nixon Peabody Trust reported no remaining AC Immune position as of Q1 2024 after selling out during the quarter.
Nixon Peabody Trust sold 12,850 AC Immune shares in Q1 2024, an estimated $64.3K.
Nixon Peabody Trust first reported a position in AC Immune in Q4 2023 and held it in 1 quarter.
Nixon Peabody Trust's AC Immune position peaked at $64.3K in Q4 2023.
37 funds tracked by Wall St. Rank held AC Immune as of Q1 2024.

Based on Nixon Peabody Trust's 13F filing for Q1 2024, filed 7 May 2024.